Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
no the market will kill this one
gonna take a lot of amalgamated filling to close that 30% down gap
plan does not execute as planned
commoner pays the price
robbing peter to pay paul
page 6 of the prosp add it up
its like 230m after warrants and comps
r/s by sept
oh yea
this is the buy the fear part
this is the part i like the best part
the buy the fear part
hello .09s
don't forget products
gotta buy some products
and tell a few friends
act think tweet tweet
ralph
yours now
lol they burn a mil a month
maybe take a break from posting for a while even
just sayin
damaj started company with $3m in loans
$2m loc that stays at 100%
$30k/month interest to damaj
enormous sg&a that cuts margins to 12% NET
beyond human not far from mlm scheme
1.12 spent for every 1 earned
diluted 100% in 2016 and will again in 2017 = o/s 280m
r/s on uplist and grant preferred convertible shares to insiders
dump warrant shares on every pr
forget about the 13m .25s????
they're still there waiting for volume
current s1 if effective maxes a/s and novalere holders will sell at first chance
they have royalties coming
why tell the truth?
my interest shares are @ .0092 from smart trading
butwhatdoestheoldmanknow
no action all are trapped goodbye money
killing it here
great 60% swings
he wants to sell and be done with the shares
royals will do quite nice
ps-nice tits sarah
no slow drift to no bid and extinction
We recognized sales and marketing expense of approximately $3.6 million for the year ended December 31, 2016
We recognized general and administrative expense of approximately $5.9 million for the year ended December 31, 2016
We recognized interest expense of approximately $6.7 million for the year ended December 31, 2016
all you need to know
nemus patent for suppository 14/462482 has been granted
02-16-2017 Mail Notice of Allowance
cemented partnership with Catalent
announcement forthcoming?
won't move stock as nemus doesn't pump wire prs
nemus has no cash
series preffereds were a disaster
.50 warrants cut to .40 then .25
all warrants now priced @ .25
co burns $2m/Q
who is nemus? not nemus bioscience, inc. murphy's co nemus?
scamitty scam-scam spam-scam
private founders can't obtain traditional financing
buy cheap shell to capitalize on public markets
max-out A/S on dilutive funding on promises of acquisitions and future revs (comming soon!)
R/S commons and recapitalize with preferred shares
issue preferred to founders to keep control
take co dark when public fleecing is no longer necessary
reap profits from their private-public venture
beware when a co says, "we expect to release big news soon!"
pump-n-dump
this is exactly correct
no bid very soon
all over for oclg
.32 to .47
Coming back @ .42
Slowest week since last April when the accumulation started to pay-off...n' I sold you your .60s
And the pps right at +50%...whattayouknow?
Got back my 1.6M under .20, plus 1.4M freebies. I'll take another mil cost-free if the stagnation avails. This time I'll exit with $7M
But what do I know?
§
The real Ad-Rock says...
Hey team, still here just on vacay for the month. I was in cash going into the events and the popcorn sucked. Many disappointments about how things were handled and turned out. I'll be back after Labor Day. Stay on your toes, there is patent updates and nobody's on it!
Best to all!
§
Hey orveko, what do you make of the response filed today?
U.S. Pat. App. No. 14/395581
I'm too drunk!
§
I think the IP issue is preventing us from partnering A2-73 in AD. The compound is public domain and it might take some exclusivity strategy to get a deal.
Collaboration in one of the orphan indications may come first. The validation of the A2-73 MOA is necessary to capitalize on A3-71, where we have exclusive rights.
If this was a one-trick pony, I'd be long gone. Sacrifice in the name of the "pearl of inestimable value" is probably more the reality.
We are funded through next year. $5 is still a good valuation.
"Ahead captain?"..."Ahead all-full, Mr Sulu...warp speed"
GLTA
§
The market never fails to impress. The short attack was pre-planned, as usual, and brings us right back where we were at the beginning of the year. No surprise there.
I think the data looks great. But, without some undeniable, inexpiable and irrefutable evidence of an absolute cure...the N=27 will get no respect. So, in-line with our small trial being absolutely meaningless to the market...
Anavex 2-73 met it's primary and secondary outcomes in it's P2a. That is a fact...and all that really matters. The chances that this data release was going to make a P3 a "formality" was less than that which the 99% AD failure rate offers. We have a "Completed, with results" feather in our CT cap, and that means something.
Personal opinions? In assuming none of the 7 patients not on donepezil were dropouts, and also assuming they were MCI-stage, it appears the MMSE score for this group actually improved over baseline at 31 weeks. The other A2-73 vs PLUS data also seems to suggest that the don-naive patients were diagnosed MCI and not mild-moderate. That starts to fall in line with other studies which suggest the treatment may be more effective in mild cases, and once the disease gets to a certain point it's cascade is unstoppable.
If the response is not an effect of a higher baseline/MCI/don-naive subset group, but rather contains some mild-moderate patients who just happened not to already be on don, then there may be evidence of the AChEI actually inhibiting the efficacy of the A2-73 monotherapy.
The overall scores at 31 weeks are outstanding. We only have the 26-week ABIL-ROCS trial to compare against and at 26 weeks it looks like we did about 26% better.
The cogstate results are still looking favorable and this is a very objective and precision set of tests.
The cohort size may be small, but we are attempting to capture data for three years. If we can keep retention to 16 for that length, the placebo effect will be reduced to 2% and results will be solid.
I see no reason to believe our catalysts will cease. A2-73 in AD as a sacrificial lamb has always been the plan, IMO. I paid attention to an expert in the field today. He did not italicize for nothing!
“This clinical data together with prior preclinical findings seem to confirm ANAVEX 2-73’s selective activation of the specific stress reducing and survival protein, Sigma-1 receptor. This seems to present a potential common pathway for rescuing major neurodevelopmental and neurodegenerative disease mechanisms, like in Autism-related disorders and Alzheimer’s disease. I believe the distinct mechanistic nature suggests the compound could be a candidate treatment for a precision medicine approach across a spectrum of different neurological and psychiatric diseases,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board.
“By utilizing an adaptive design in our current ANAVEX 2-73 Phase 2a study, the treatment was finely adapted to the patient’s response, sparing patients from unnecessary side effects and safeguarding patients’ well-being, as evidenced by a high retention rate in this maximum tolerated dose (MTD) study,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “We are encouraged to proceed with the plan to confirm the data in a larger Phase 2/3 trial, for which planning is underway.”
Just another day in bioland...hang in there kids!
§
Sorry, can't post and trade at the same time!
Long and strong!
Well, I agree with you TomP1. The trials should have been designed better, too. Adaptive, less costly. Could have saved some programs.
I maintain the company here believed in the MOA enough to attract a CEO who could overcome the perils of P3 AD approval. He plays a good game of chess and is going for all the marbles. If 2-73 makes a splash, 3-71 will drain the pool.
Speaking of "gingers'...our lil' redhead keeps getting knocked to the canvas, but gets back up and starts swinging again.
Go LOA!
§
Train's leaving the station! §
Sweet..the LMNX 21.66 payout!!! §
They fuck-up your weekend and every-damn thing...this one.
AD SOC. No problem.
§
Nobody shorts OTC stocks...but they get traded like that one girlfriend you had
§
1:00ET boom-time. You cook the popcorn in a Jamaican cast iron pot...they're, like, 40qt. Straight coconut oil...save the butter for drizzling. Make sure it's skim-clarified Pure sea salt added right as the corn starts to pop. Put the pot on the raft, grab the punch, head-out onto the surf and watch the show!
§
goodluckwiththat...§
Correct. No way you go off the 5d RSI here. 3m is 86 and much better indicator vs volume metrics. And yes...overbought.
§
Perhaps due to reduced muscarinic signaling in the OB. We're on it...!
https://www.google.com/search?q=muscarinic+receptors+olfactory&ie=utf-8&oe=utf-8
§
Please do. I have a couple 100K markers of this garbage and want it off the radar. So SCPAM IT UP!!!!
GLTA
§
Did XCOM for $278K yesterday...a KOOL $78K today.
Loving life! INNV up 378% on the 20% HCA!
§
BOO-YA! $80M and $30M of credit!!! Holding 1.6M @ .32 Let the good times roll!
§